Disposal:

Dispose of any unused product or containers in accordance with guidance from your local waste regulation authority, eg the local regional office of the Environment Agency or SEPA.

End user should be advised that any remaining after the course of treatment should be returned to the veterinary surgery.

Phenylbutazone 200 mg should not be administered to dogs weighing less than 20 kg bodyweight.

Do not exceed the stated dose or the duration of treatment.

Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.

NSAID's can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate antimicrobial therapy should be instigated.

Not to be used in cats.

Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided.

In suspected cases of renal or hepatic dysfunction an EDTA and clotted blood sample should be taken in order that relevant haematological and biochemical assays can be carried out prior to commencement of treatment.

Treatment should be discontinued in animals developing gastrointestinal symptoms or vascular disorders.

It is preferable that NSAID's which inhibit prostaglandin synthesis are not administered to animals undergoing anaesthesia until fully recovered.